Indexado en

Licencia y uso

Citaciones

Cited 76 times in

Cited 66 times in

Cited 40 times in

Cited 72 times in

Altmetrics

Grant support

This work was supported, in part, by grants from the Deutsche Forschungsgemeinschaft (DFG; QU144/1-1 [L.Q.-M.], FE597/4-1 [F.F.], and QU144/1-1 [I.M.]), Fondo de Investigaciones Sanitarias Instituto de Salud Carlos III (Miguel Servet Program CP13/00159 and PI15/00580, [I.S.]). J.E.R.-Z. was supported by a fellowship from theGeneralitat deCatalunyaAgencia de Gestion de la Universidad la Investigacion (AGAUR) FI-DGR 2017 (2017 FI_B01004). E.C. is an Academia Researcher of the Institucio Catalana de Recerca I Estudis Avancats (ICREA) of the Generalitat de Catalunya. This work was partially developed at the Centro Esther Koplowitz, Barcelona, Spain. I.S. is supported by Accio Instrumental d'Incorporacio de Cientifics i Tecnolegs Plan de Investigacion e Innovacion en Salud (PERIS) 2016 (SLT002/16/00336) from the Generalitat de Catalunya.

Análisis de autorías institucional

Compartir

Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease

Publicado en:Blood Advances. 4 (22): 5652-5665 - 2020-11-24 4(22), DOI: 10.1182/bloodadvances.2020002944

Autores: Nann, Dominik; Ramis-Zaldivar, Joan Enric; Muller, Inga; Gonzalez-Farre, Blanca; Schmidt, Janine; Egan, Caoimhe; Salmeron-Villalobos, Julia; Clot, Guillem; Mattern, Sven; Otto, Franziska; Mankel, Barbara; Colomer, Dolors; Balague, Olga; Szablewski, Vanessa; Lome-Maldonado, Carmen; Leoncini, Lorenzo; Dojcinov, Stefan; Chott, Andreas; Copie-Bergman, Christiane; Bonzheim, Irina; Fend, Falko; Jaffe, Elaine S; Campo, Elias; Salaverria, Itziar; Quintanilla-Martinez, Leticia

Afiliaciones

Resumen

Fifty-five cases of t(14;18)- follicular lymphoma (FL) were genetically characterized by targeted sequencing and copy number (CN) arrays. t(14;18)- FL predominated in women (M/F 1:2); patients often presented during early clinical stages (71%), and had excellent prognoses. Overall, t(14;18)- FL displayed CN alterations (CNAs) and gene mutations carried by conventional t(14;18)+ FL (cFL), but with different frequencies. The most frequently mutated gene was STAT6 (57%) followed by CREBBP (49%), TNFRSF14 (39%), and KMT2D (27%). t(14;18)- FL showed significantly more STAT6 mutations and lacked MYD88, NOTCH2, MEF2B, and MAP2K1 mutations compared with cFL, nodal marginal zone lymphoma (NMZL), and pediatric-type FL (PTFL). We identified 2 molecular clusters. Cluster A was characterized by TNFRSF14 mutations/1p36 alterations (96%) and frequent mutations in epigenetic regulators, with recurrent loss of 6q21-24 sharing many features with cFL. Cluster B showed few genetic alterations; however, a subgroup with STAT6 mutations concurrent with CREBBP mutations/16p alterations without TNFRSF14 and EZH2 mutations was noted (65%). These 2 molecular clusters did not distinguish cases by inguinal localization, growth pattern, or presence of STAT6 mutations. BCL6 rearrangements were demonstrated in 10 of 45 (22%) cases and did not cluster together. Cases with predominantly inguinal presentation (20 of 50; 40%) had a higher frequency of diffuse growth pattern, STAT6 mutations, CD23 expression, and a lower number of CNAs, in comparison with noninguinal cases (5.1 vs 9.1 alterations per case; P < .05). STAT6 mutations showed a positive correlation with CD23 expression (P < .001). In summary, t(14;18)- FL is genetically a heterogeneous disorder with features that differ from cFL, NMZL, and PTFL.

Palabras clave